APO Research
Talk to an analyst

APO RESEARCH · REPORT

Medicine for Osteoarthritis Pain

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Medicine for Osteoarthritis Pain Market Outlook and Growth Opportunities 2026

21 December 2025203 pages

Choose your research edition.

Industry ResearchMedicine for Osteoarthritis Pain Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Medicine for Osteoarthritis Pain Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Medicine for Osteoarthritis Pain Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Medicine for Osteoarthritis Pain Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Medicine for Osteoarthritis Pain Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Medicine for Osteoarthritis Pain market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Medicine for Osteoarthritis Pain is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Medicine for Osteoarthritis Pain is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Medicine for Osteoarthritis Pain is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Medicine for Osteoarthritis Pain market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Medicine for Osteoarthritis Pain market include Abbott, TEVA, Sanofi, Johnson and Johnson, Novartis, Mylan, Eli Lilly, Hengrui Pharmaceutical and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Medicine for Osteoarthritis Pain market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Medicine for Osteoarthritis Pain and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Medicine for Osteoarthritis Pain sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Medicine for Osteoarthritis Pain market size, projected growth trends, production technologies, key applications, and end-use industries.

Medicine for Osteoarthritis Pain Segment by Company

Abbott

TEVA

Sanofi

Johnson and Johnson

Novartis

Mylan

Eli Lilly

Hengrui Pharmaceutical

Pfizer

GlaxoSmithKline

Daiichi Sankyo

Bayer

Tide Pharmaceutical

Iroko Pharmaceuticals

Horizon Pharma

Astellas Pharma

Almatica Pharma

Abiogen Pharma

Medicine for Osteoarthritis Pain Segment by Type

Injection

External

Oral

Medicine for Osteoarthritis Pain Segment by Application

Medical Care

Personal Care

Medicine for Osteoarthritis Pain Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Medicine for Osteoarthritis Pain status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Medicine for Osteoarthritis Pain market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Medicine for Osteoarthritis Pain significant trends, drivers, influence factors in global and regions.

6. To analyze Medicine for Osteoarthritis Pain competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medicine for Osteoarthritis Pain market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Medicine for Osteoarthritis Pain and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medicine for Osteoarthritis Pain.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Medicine for Osteoarthritis Pain market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Medicine for Osteoarthritis Pain industry.

Chapter 3: Detailed analysis of Medicine for Osteoarthritis Pain manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Medicine for Osteoarthritis Pain in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Medicine for Osteoarthritis Pain in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Medicine for Osteoarthritis Pain Industry Trends Table 2. Medicine for Osteoarthritis Pain Industry Drivers Table 3. Medicine for Osteoarthritis Pain Industry Opportunities and Challenges Table 4. Medicine for Osteoarthritis Pain Industry Restraints Table 5. Global Medicine for Osteoarthritis Pain Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Medicine for Osteoarthritis Pain Revenue Share by Company (2021-2026) Table 7. Global Medicine for Osteoarthritis Pain Sales Volume by Company (k units) & (2021-2026) Table 8. Global Medicine for Osteoarthritis Pain Sales Volume Share by Company (2021-2026) Table 9. Global Medicine for Osteoarthritis Pain Average Price (US$/unit) of Company (2021-2026) Table 10. Global Medicine for Osteoarthritis Pain Company Ranking, (2024-2026) & (USD Million) Table 11. Global Medicine for Osteoarthritis Pain Key Company Manufacturing Base & Headquarters Table 12. Global Medicine for Osteoarthritis Pain Company, Product Type & Application Table 13. Global Medicine for Osteoarthritis Pain Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Medicine for Osteoarthritis Pain by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Injection Table 18. Significant Companies of External Table 19. Significant Companies of Oral Table 20. Global Medicine for Osteoarthritis Pain Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Medicine for Osteoarthritis Pain Sales Volume by Type (2021-2026) & (k units) Table 22. Global Medicine for Osteoarthritis Pain Sales Volume by Type (2027-2032) & (k units) Table 23. Global Medicine for Osteoarthritis Pain Sales Volume Share by Type (2021-2026) Table 24. Global Medicine for Osteoarthritis Pain Sales Volume Share by Type (2027-2032) Table 25. Global Medicine for Osteoarthritis Pain Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Medicine for Osteoarthritis Pain Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Medicine for Osteoarthritis Pain Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Medicine for Osteoarthritis Pain Sales Value Share by Type (2021-2026) Table 29. Global Medicine for Osteoarthritis Pain Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Medical Care Table 31. Significant Companies of Personal Care Table 32. Global Medicine for Osteoarthritis Pain Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Medicine for Osteoarthritis Pain Sales Volume by Application (2021-2026) & (k units) Table 34. Global Medicine for Osteoarthritis Pain Sales Volume by Application (2027-2032) & (k units) Table 35. Global Medicine for Osteoarthritis Pain Sales Volume Share by Application (2021-2026) Table 36. Global Medicine for Osteoarthritis Pain Sales Volume Share by Application (2027-2032) Table 37. Global Medicine for Osteoarthritis Pain Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Medicine for Osteoarthritis Pain Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Medicine for Osteoarthritis Pain Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Medicine for Osteoarthritis Pain Sales Value Share by Application (2021-2026) Table 41. Global Medicine for Osteoarthritis Pain Sales Value Share by Application (2027-2032) Table 42. Global Medicine for Osteoarthritis Pain Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Medicine for Osteoarthritis Pain Sales by Region (2021-2026) & (k units) Table 44. Global Medicine for Osteoarthritis Pain Sales Market Share by Region (2021-2026) Table 45. Global Medicine for Osteoarthritis Pain Sales by Region (2027-2032) & (k units) Table 46. Global Medicine for Osteoarthritis Pain Sales Market Share by Region (2027-2032) Table 47. Global Medicine for Osteoarthritis Pain Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Medicine for Osteoarthritis Pain Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Medicine for Osteoarthritis Pain Sales Value Share by Region (2021-2026) Table 50. Global Medicine for Osteoarthritis Pain Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Medicine for Osteoarthritis Pain Sales Value Share by Region (2027-2032) Table 52. Global Medicine for Osteoarthritis Pain Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Medicine for Osteoarthritis Pain Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Medicine for Osteoarthritis Pain Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Medicine for Osteoarthritis Pain Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Medicine for Osteoarthritis Pain Sales by Country (2021-2026) & (k units) Table 57. Global Medicine for Osteoarthritis Pain Sales Market Share by Country (2021-2026) Table 58. Global Medicine for Osteoarthritis Pain Sales by Country (2027-2032) & (k units) Table 59. Global Medicine for Osteoarthritis Pain Sales Market Share by Country (2027-2032) Table 60. Global Medicine for Osteoarthritis Pain Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Medicine for Osteoarthritis Pain Sales Value Market Share by Country (2021-2026) Table 62. Global Medicine for Osteoarthritis Pain Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Medicine for Osteoarthritis Pain Sales Value Market Share by Country (2027-2032) Table 64. Abbott Company Information Table 65. Abbott Business Overview Table 66. Abbott Medicine for Osteoarthritis Pain Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Abbott Medicine for Osteoarthritis Pain Product Portfolio Table 68. Abbott Recent Development Table 69. TEVA Company Information Table 70. TEVA Business Overview Table 71. TEVA Medicine for Osteoarthritis Pain Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. TEVA Medicine for Osteoarthritis Pain Product Portfolio Table 73. TEVA Recent Development Table 74. Sanofi Company Information Table 75. Sanofi Business Overview Table 76. Sanofi Medicine for Osteoarthritis Pain Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Sanofi Medicine for Osteoarthritis Pain Product Portfolio Table 78. Sanofi Recent Development Table 79. Johnson and Johnson Company Information Table 80. Johnson and Johnson Business Overview Table 81. Johnson and Johnson Medicine for Osteoarthritis Pain Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Johnson and Johnson Medicine for Osteoarthritis Pain Product Portfolio Table 83. Johnson and Johnson Recent Development Table 84. Novartis Company Information Table 85. Novartis Business Overview Table 86. Novartis Medicine for Osteoarthritis Pain Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Novartis Medicine for Osteoarthritis Pain Product Portfolio Table 88. Novartis Recent Development Table 89. Mylan Company Information Table 90. Mylan Business Overview Table 91. Mylan Medicine for Osteoarthritis Pain Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Mylan Medicine for Osteoarthritis Pain Product Portfolio Table 93. Mylan Recent Development Table 94. Eli Lilly Company Information Table 95. Eli Lilly Business Overview Table 96. Eli Lilly Medicine for Osteoarthritis Pain Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Eli Lilly Medicine for Osteoarthritis Pain Product Portfolio Table 98. Eli Lilly Recent Development Table 99. Hengrui Pharmaceutical Company Information Table 100. Hengrui Pharmaceutical Business Overview Table 101. Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Product Portfolio Table 103. Hengrui Pharmaceutical Recent Development Table 104. Pfizer Company Information Table 105. Pfizer Business Overview Table 106. Pfizer Medicine for Osteoarthritis Pain Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Pfizer Medicine for Osteoarthritis Pain Product Portfolio Table 108. Pfizer Recent Development Table 109. GlaxoSmithKline Company Information Table 110. GlaxoSmithKline Business Overview Table 111. GlaxoSmithKline Medicine for Osteoarthritis Pain Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. GlaxoSmithKline Medicine for Osteoarthritis Pain Product Portfolio Table 113. GlaxoSmithKline Recent Development Table 114. Daiichi Sankyo Company Information Table 115. Daiichi Sankyo Business Overview Table 116. Daiichi Sankyo Medicine for Osteoarthritis Pain Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Daiichi Sankyo Medicine for Osteoarthritis Pain Product Portfolio Table 118. Daiichi Sankyo Recent Development Table 119. Bayer Company Information Table 120. Bayer Business Overview Table 121. Bayer Medicine for Osteoarthritis Pain Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Bayer Medicine for Osteoarthritis Pain Product Portfolio Table 123. Bayer Recent Development Table 124. Tide Pharmaceutical Company Information Table 125. Tide Pharmaceutical Business Overview Table 126. Tide Pharmaceutical Medicine for Osteoarthritis Pain Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Tide Pharmaceutical Medicine for Osteoarthritis Pain Product Portfolio Table 128. Tide Pharmaceutical Recent Development Table 129. Iroko Pharmaceuticals Company Information Table 130. Iroko Pharmaceuticals Business Overview Table 131. Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Product Portfolio Table 133. Iroko Pharmaceuticals Recent Development Table 134. Horizon Pharma Company Information Table 135. Horizon Pharma Business Overview Table 136. Horizon Pharma Medicine for Osteoarthritis Pain Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Horizon Pharma Medicine for Osteoarthritis Pain Product Portfolio Table 138. Horizon Pharma Recent Development Table 139. Astellas Pharma Company Information Table 140. Astellas Pharma Business Overview Table 141. Astellas Pharma Medicine for Osteoarthritis Pain Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. Astellas Pharma Medicine for Osteoarthritis Pain Product Portfolio Table 143. Astellas Pharma Recent Development Table 144. Almatica Pharma Company Information Table 145. Almatica Pharma Business Overview Table 146. Almatica Pharma Medicine for Osteoarthritis Pain Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 147. Almatica Pharma Medicine for Osteoarthritis Pain Product Portfolio Table 148. Almatica Pharma Recent Development Table 149. Abiogen Pharma Company Information Table 150. Abiogen Pharma Business Overview Table 151. Abiogen Pharma Medicine for Osteoarthritis Pain Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 152. Abiogen Pharma Medicine for Osteoarthritis Pain Product Portfolio Table 153. Abiogen Pharma Recent Development Table 154. Key Raw Materials Table 155. Raw Materials Key Suppliers Table 156. Medicine for Osteoarthritis Pain Distributors List Table 157. Medicine for Osteoarthritis Pain Customers List Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Medicine for Osteoarthritis Pain Product Image Figure 2. Global Medicine for Osteoarthritis Pain Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Medicine for Osteoarthritis Pain Sales Value (2021-2032) & (US$ Million) Figure 4. Global Medicine for Osteoarthritis Pain Sales (2021-2032) & (k units) Figure 5. Global Medicine for Osteoarthritis Pain Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Medicine for Osteoarthritis Pain Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Injection Image Figure 10. External Image Figure 11. Oral Image Figure 12. Global Medicine for Osteoarthritis Pain Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Medicine for Osteoarthritis Pain Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Medicine for Osteoarthritis Pain Sales Volume Share by Type (2021-2032) Figure 15. Global Medicine for Osteoarthritis Pain Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Medicine for Osteoarthritis Pain Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Medicine for Osteoarthritis Pain Sales Value Share by Type (2021-2032) Figure 18. Medical Care Image Figure 19. Personal Care Image Figure 20. Global Medicine for Osteoarthritis Pain Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Medicine for Osteoarthritis Pain Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Medicine for Osteoarthritis Pain Sales Volume Share by Application (2021-2032) Figure 23. Global Medicine for Osteoarthritis Pain Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Medicine for Osteoarthritis Pain Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Medicine for Osteoarthritis Pain Sales Value Share by Application (2021-2032) Figure 26. Global Medicine for Osteoarthritis Pain Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Medicine for Osteoarthritis Pain Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Medicine for Osteoarthritis Pain Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Medicine for Osteoarthritis Pain Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Medicine for Osteoarthritis Pain Sales Value (2021-2032) & (US$ Million) Figure 31. North America Medicine for Osteoarthritis Pain Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Medicine for Osteoarthritis Pain Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Medicine for Osteoarthritis Pain Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Medicine for Osteoarthritis Pain Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Medicine for Osteoarthritis Pain Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Medicine for Osteoarthritis Pain Sales Value (2021-2032) & (US$ Million) Figure 37. South America Medicine for Osteoarthritis Pain Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Medicine for Osteoarthritis Pain Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Medicine for Osteoarthritis Pain Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Medicine for Osteoarthritis Pain Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Medicine for Osteoarthritis Pain Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • External
  • Oral
Applications
  • Medical Care
  • Personal Care
Companies covered
  • Abbott
  • TEVA
  • Sanofi
  • Johnson and Johnson
  • Novartis
  • Mylan
  • Eli Lilly
  • Hengrui Pharmaceutical
  • Pfizer
  • GlaxoSmithKline
  • Daiichi Sankyo
  • Bayer
  • Tide Pharmaceutical
  • Iroko Pharmaceuticals
  • Horizon Pharma
  • Astellas Pharma
  • Almatica Pharma
  • Abiogen Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Medicine for Osteoarthritis Pain Sales Value (2021-2032)
  4. 1.2.2 Global Medicine for Osteoarthritis Pain Sales Volume (2021-2032)
  5. 1.2.3 Global Medicine for Osteoarthritis Pain Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Medicine for Osteoarthritis Pain Market Dynamics
  1. 2.1 Medicine for Osteoarthritis Pain Industry Trends
  2. 2.2 Medicine for Osteoarthritis Pain Industry Drivers
  3. 2.3 Medicine for Osteoarthritis Pain Industry Opportunities and Challenges
  4. 2.4 Medicine for Osteoarthritis Pain Industry Restraints
3 Medicine for Osteoarthritis Pain Market by Company
  1. 3.1 Global Medicine for Osteoarthritis Pain Company Revenue Ranking in 2025
  2. 3.2 Global Medicine for Osteoarthritis Pain Revenue by Company (2021-2026)
  3. 3.3 Global Medicine for Osteoarthritis Pain Sales Volume by Company (2021-2026)
  4. 3.4 Global Medicine for Osteoarthritis Pain Average Price by Company (2021-2026)
  5. 3.5 Global Medicine for Osteoarthritis Pain Company Ranking (2024-2026)
  6. 3.6 Global Medicine for Osteoarthritis Pain Company Manufacturing Base and Headquarters
  7. 3.7 Global Medicine for Osteoarthritis Pain Company Product Type and Application
  8. 3.8 Global Medicine for Osteoarthritis Pain Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Medicine for Osteoarthritis Pain Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Medicine for Osteoarthritis Pain Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Medicine for Osteoarthritis Pain Market by Type
  1. 4.1 Medicine for Osteoarthritis Pain Type Introduction
  2. 4.1.1 Injection
  3. 4.1.2 External
  4. 4.1.3 Oral
  5. 4.2 Global Medicine for Osteoarthritis Pain Sales Volume by Type
  6. 4.2.1 Global Medicine for Osteoarthritis Pain Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Medicine for Osteoarthritis Pain Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Medicine for Osteoarthritis Pain Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Medicine for Osteoarthritis Pain Sales Value by Type
  10. 4.3.1 Global Medicine for Osteoarthritis Pain Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Medicine for Osteoarthritis Pain Sales Value by Type (2021-2032)
  12. 4.3.3 Global Medicine for Osteoarthritis Pain Sales Value Share by Type (2021-2032)
5 Medicine for Osteoarthritis Pain Market by Application
  1. 5.1 Medicine for Osteoarthritis Pain Application Introduction
  2. 5.1.1 Medical Care
  3. 5.1.2 Personal Care
  4. 5.2 Global Medicine for Osteoarthritis Pain Sales Volume by Application
  5. 5.2.1 Global Medicine for Osteoarthritis Pain Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Medicine for Osteoarthritis Pain Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Medicine for Osteoarthritis Pain Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Medicine for Osteoarthritis Pain Sales Value by Application
  9. 5.3.1 Global Medicine for Osteoarthritis Pain Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Medicine for Osteoarthritis Pain Sales Value by Application (2021-2032)
  11. 5.3.3 Global Medicine for Osteoarthritis Pain Sales Value Share by Application (2021-2032)
6 Medicine for Osteoarthritis Pain Regional Sales and Value Analysis
  1. 6.1 Global Medicine for Osteoarthritis Pain Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Medicine for Osteoarthritis Pain Sales by Region (2021-2032)
  3. 6.2.1 Global Medicine for Osteoarthritis Pain Sales by Region: 2021-2026
  4. 6.2.2 Global Medicine for Osteoarthritis Pain Sales by Region (2027-2032)
  5. 6.3 Global Medicine for Osteoarthritis Pain Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Medicine for Osteoarthritis Pain Sales Value by Region (2021-2032)
  7. 6.4.1 Global Medicine for Osteoarthritis Pain Sales Value by Region: 2021-2026
  8. 6.4.2 Global Medicine for Osteoarthritis Pain Sales Value by Region (2027-2032)
  9. 6.5 Global Medicine for Osteoarthritis Pain Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Medicine for Osteoarthritis Pain Sales Value (2021-2032)
  12. 6.6.2 North America Medicine for Osteoarthritis Pain Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Medicine for Osteoarthritis Pain Sales Value (2021-2032)
  15. 6.7.2 Europe Medicine for Osteoarthritis Pain Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Medicine for Osteoarthritis Pain Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Medicine for Osteoarthritis Pain Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Medicine for Osteoarthritis Pain Sales Value (2021-2032)
  21. 6.9.2 South America Medicine for Osteoarthritis Pain Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Medicine for Osteoarthritis Pain Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Medicine for Osteoarthritis Pain Sales Value Share by Country, 2025 VS 2032
7 Medicine for Osteoarthritis Pain Country-level Sales and Value Analysis
  1. 7.1 Global Medicine for Osteoarthritis Pain Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Medicine for Osteoarthritis Pain Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Medicine for Osteoarthritis Pain Sales by Country (2021-2032)
  4. 7.3.1 Global Medicine for Osteoarthritis Pain Sales by Country (2021-2026)
  5. 7.3.2 Global Medicine for Osteoarthritis Pain Sales by Country (2027-2032)
  6. 7.4 Global Medicine for Osteoarthritis Pain Sales Value by Country (2021-2032)
  7. 7.4.1 Global Medicine for Osteoarthritis Pain Sales Value by Country (2021-2026)
  8. 7.4.2 Global Medicine for Osteoarthritis Pain Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Medicine for Osteoarthritis Pain Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Medicine for Osteoarthritis Pain Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Medicine for Osteoarthritis Pain Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Medicine for Osteoarthritis Pain Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Medicine for Osteoarthritis Pain Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 TEVA
  8. 8.2.1 TEVA Company Information
  9. 8.2.2 TEVA Business Overview
  10. 8.2.3 TEVA Medicine for Osteoarthritis Pain Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 TEVA Medicine for Osteoarthritis Pain Product Portfolio
  12. 8.2.5 TEVA Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Medicine for Osteoarthritis Pain Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Medicine for Osteoarthritis Pain Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson and Johnson
  20. 8.4.1 Johnson and Johnson Company Information
  21. 8.4.2 Johnson and Johnson Business Overview
  22. 8.4.3 Johnson and Johnson Medicine for Osteoarthritis Pain Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Johnson and Johnson Medicine for Osteoarthritis Pain Product Portfolio
  24. 8.4.5 Johnson and Johnson Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Medicine for Osteoarthritis Pain Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Medicine for Osteoarthritis Pain Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Mylan
  32. 8.6.1 Mylan Company Information
  33. 8.6.2 Mylan Business Overview
  34. 8.6.3 Mylan Medicine for Osteoarthritis Pain Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Mylan Medicine for Osteoarthritis Pain Product Portfolio
  36. 8.6.5 Mylan Recent Developments
  37. 8.7 Eli Lilly
  38. 8.7.1 Eli Lilly Company Information
  39. 8.7.2 Eli Lilly Business Overview
  40. 8.7.3 Eli Lilly Medicine for Osteoarthritis Pain Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Eli Lilly Medicine for Osteoarthritis Pain Product Portfolio
  42. 8.7.5 Eli Lilly Recent Developments
  43. 8.8 Hengrui Pharmaceutical
  44. 8.8.1 Hengrui Pharmaceutical Company Information
  45. 8.8.2 Hengrui Pharmaceutical Business Overview
  46. 8.8.3 Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Hengrui Pharmaceutical Medicine for Osteoarthritis Pain Product Portfolio
  48. 8.8.5 Hengrui Pharmaceutical Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Medicine for Osteoarthritis Pain Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Medicine for Osteoarthritis Pain Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 GlaxoSmithKline
  56. 8.10.1 GlaxoSmithKline Company Information
  57. 8.10.2 GlaxoSmithKline Business Overview
  58. 8.10.3 GlaxoSmithKline Medicine for Osteoarthritis Pain Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 GlaxoSmithKline Medicine for Osteoarthritis Pain Product Portfolio
  60. 8.10.5 GlaxoSmithKline Recent Developments
  61. 8.11 Daiichi Sankyo
  62. 8.11.1 Daiichi Sankyo Company Information
  63. 8.11.2 Daiichi Sankyo Business Overview
  64. 8.11.3 Daiichi Sankyo Medicine for Osteoarthritis Pain Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Daiichi Sankyo Medicine for Osteoarthritis Pain Product Portfolio
  66. 8.11.5 Daiichi Sankyo Recent Developments
  67. 8.12 Bayer
  68. 8.12.1 Bayer Company Information
  69. 8.12.2 Bayer Business Overview
  70. 8.12.3 Bayer Medicine for Osteoarthritis Pain Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Bayer Medicine for Osteoarthritis Pain Product Portfolio
  72. 8.12.5 Bayer Recent Developments
  73. 8.13 Tide Pharmaceutical
  74. 8.13.1 Tide Pharmaceutical Company Information
  75. 8.13.2 Tide Pharmaceutical Business Overview
  76. 8.13.3 Tide Pharmaceutical Medicine for Osteoarthritis Pain Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Tide Pharmaceutical Medicine for Osteoarthritis Pain Product Portfolio
  78. 8.13.5 Tide Pharmaceutical Recent Developments
  79. 8.14 Iroko Pharmaceuticals
  80. 8.14.1 Iroko Pharmaceuticals Company Information
  81. 8.14.2 Iroko Pharmaceuticals Business Overview
  82. 8.14.3 Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Iroko Pharmaceuticals Medicine for Osteoarthritis Pain Product Portfolio
  84. 8.14.5 Iroko Pharmaceuticals Recent Developments
  85. 8.15 Horizon Pharma
  86. 8.15.1 Horizon Pharma Company Information
  87. 8.15.2 Horizon Pharma Business Overview
  88. 8.15.3 Horizon Pharma Medicine for Osteoarthritis Pain Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Horizon Pharma Medicine for Osteoarthritis Pain Product Portfolio
  90. 8.15.5 Horizon Pharma Recent Developments
  91. 8.16 Astellas Pharma
  92. 8.16.1 Astellas Pharma Company Information
  93. 8.16.2 Astellas Pharma Business Overview
  94. 8.16.3 Astellas Pharma Medicine for Osteoarthritis Pain Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Astellas Pharma Medicine for Osteoarthritis Pain Product Portfolio
  96. 8.16.5 Astellas Pharma Recent Developments
  97. 8.17 Almatica Pharma
  98. 8.17.1 Almatica Pharma Company Information
  99. 8.17.2 Almatica Pharma Business Overview
  100. 8.17.3 Almatica Pharma Medicine for Osteoarthritis Pain Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Almatica Pharma Medicine for Osteoarthritis Pain Product Portfolio
  102. 8.17.5 Almatica Pharma Recent Developments
  103. 8.18 Abiogen Pharma
  104. 8.18.1 Abiogen Pharma Company Information
  105. 8.18.2 Abiogen Pharma Business Overview
  106. 8.18.3 Abiogen Pharma Medicine for Osteoarthritis Pain Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Abiogen Pharma Medicine for Osteoarthritis Pain Product Portfolio
  108. 8.18.5 Abiogen Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Medicine for Osteoarthritis Pain Value Chain Analysis
  2. 9.1.1 Medicine for Osteoarthritis Pain Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Medicine for Osteoarthritis Pain Sales Mode & Process
  6. 9.2 Medicine for Osteoarthritis Pain Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Medicine for Osteoarthritis Pain Distributors
  9. 9.2.3 Medicine for Osteoarthritis Pain Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst